Prevalence and Risk Factors of Elevated Liver Enzymes in Japanese Women With Polycystic Ovary Syndrome

Overview

Journal J Clin Med Res

Specialty General Medicine

Date 2018 Nov 15

PMID 30425763

Citations 7

Authors

Satomi Minato

Naoki Sakane

Kazuhiko Kotani

Shinsuke Nirengi

Ikuyo Hayashi

Akiko Suganuma

Ken Yamaguchi

Kenji Takakura

Narumi Nagai

Affiliations

Soon will be listed here.

Abstract

Background: Polycystic ovary syndrome (PCOS) is a common endocrine disorder among reproductive-aged women. While PCOS is associated with an increased risk of obesity and insulin resistance, little is known regarding the prevalence of and risk factors for nonalcoholic fatty liver disease (NAFLD) among Japanese women with PCOS. We estimated the prevalence of and risk factors for elevated liver enzymes, as the index of NAFLD, in Japanese women with PCOS.

Methods: We retrospectively reviewed 102 reproductive-aged women who visited the Department of Gynecology, Kyoto Medical Center in Japan from January 2000 to September 2016. Inclusion criterion was confirmed diagnosis of PCOS using International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10) codes. Exclusion criteria were women with a history of liver diseases, missing body mass index (BMI) and serum alanine aminotransferase (ALT) data, and pregnancy. Data regarding age; BMI; and levels of blood glucose, serum lipid, liver enzymes, and sex hormones were obtained from medical records. Elevated liver enzymes was defined as ALT > 19 IU/L. Optimal cutoffs for risk factors for elevated liver enzymes were calculated to determine predictors of elevated liver enzymes using area under the curve (AUC) by receiver-operating characteristics (ROC).

Results: The prevalence of elevated liver enzymes was 33.3%. BMI was significantly higher in PCOS patients than in those without elevated liver enzymes (25.3 vs. 20.7 kg/m, P < 0.05). ROC analyses were performed using BMI and blood glucose and testosterone levels because BMI and blood glucose showed differences between the groups and testosterone is related to fatty liver. AUC of the model including BMI and blood glucose and testosterone levels was 0.861 (sensitivity, 66.7%; specificity, 100%).

Conclusions: These findings suggest that elevated liver enzymes are common in women with PCOS. An algorism using BMI and blood glucose and testosterone levels might be useful to determine elevated liver enzymes in women with PCOS. Our finding may be useful for the study of NAFLD among Japanese women with PCOS since several previous studies have indicated elevated liver enzymes to be related to the potential presence of NAFLD. Further examination, including abdominal ultrasonography and/or liver biopsy data, is required to confirm these results.

Citing Articles

Risk of Mental Disorders in Polycystic Ovary Syndrome: Retrospective Cohort Study of a Korean Nationwide Population-Based Cohort.

Kim Y, Chae K, Kim S, Kang S, Yoon H, Namkung J Int J Womens Health. 2025; 17:627-638.

PMID: 40061289 PMC: 11890313. DOI: 10.2147/IJWH.S490673.

Association Between Insulin Resistance Indices and Liver Function Parameters Among Women With Polycystic Ovary Syndrome.

Saei Ghare Naz M, Mousavi M, Firouzi F, Momenan A, Azizi F, Ramezani Tehrani F Endocrinol Diabetes Metab. 2024; 7(3):e490.

PMID: 38769719 PMC: 11106557. DOI: 10.1002/edm2.490.

Incidence of menstrual cycle abnormalities and polycystic ovary syndrome in female Japanese patients with type 1 diabetes mellitus. The role of androgens.

Nakamichi T, Kawamura T, Nishigaki S, Odagiri S, Yuyama Y, Nishikawa-Nakamura N Clin Pediatr Endocrinol. 2024; 33(2):59-65.

PMID: 38572387 PMC: 10985013. DOI: 10.1297/cpe.2024-0011.

The Associations Between Alanine Aminotransferase and Other Biochemical Parameters in Lean PCOS.

Liu C, Liu K, Zhao X, Zhu J, Liu Y, Hao L Reprod Sci. 2022; 30(2):633-641.

PMID: 35864417 PMC: 9988735. DOI: 10.1007/s43032-022-01030-w.

Androgen receptor coregulator long noncoding RNA CTBP1-AS is associated with polycystic ovary syndrome in Kashmiri women.

Nabi M, Andrabi S, Rasool S, Ashraf S, Majid I, Amin S Endocrine. 2021; 75(2):614-622.

PMID: 34611799 DOI: 10.1007/s12020-021-02894-9.

References

Naderian M, Kolahdoozan S, Sharifi A, Garmaroudi G, Yaseri M, Poustchi H . Assessment of Lean Patients with Non-alcoholic Fatty Liver Disease in a Middle Income Country; Prevalence and Its Association with Metabolic Disorders: A Cross-sectional Study. Arch Iran Med. 2017; 20(4):211-217. DOI: 0172004/AIM.005. View

Gomyo M, Sakane N, Kamae I, Sato S, Suzuki K, Tominaga M . Effects of sex, age and BMI on screening tests for impaired glucose tolerance. Diabetes Res Clin Pract. 2004; 64(2):129-36. DOI: 10.1016/j.diabres.2003.10.019. View

Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R . Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003; 37(4):917-23. DOI: 10.1053/jhep.2003.50161. View

Zhou Z, Li R, Qiao J . Androgen profile in Chinese women with polycystic ovary syndrome in their reproductive years. Reprod Biomed Online. 2017; 35(3):331-339. DOI: 10.1016/j.rbmo.2017.05.019. View

Gluckman P, Hanson M . Developmental origins of disease paradigm: a mechanistic and evolutionary perspective. Pediatr Res. 2004; 56(3):311-7. DOI: 10.1203/01.PDR.0000135998.08025.FB. View

Baranova A, Tran T, Afendy A, Wang L, Shamsaddini A, Mehta R . Molecular signature of adipose tissue in patients with both non-alcoholic fatty liver disease (NAFLD) and polycystic ovarian syndrome (PCOS). J Transl Med. 2013; 11:133. PMC: 3681627. DOI: 10.1186/1479-5876-11-133. View

Carmina E, Lobo R . Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab. 1999; 84(6):1897-9. DOI: 10.1210/jcem.84.6.5803. View

Gambarin-Gelwan M, Kinkhabwala S, Schiano T, Bodian C, Yeh H, Futterweit W . Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol. 2007; 5(4):496-501. DOI: 10.1016/j.cgh.2006.10.010. View

Ma R, Liu K, Lam P, Cheung L, Tam W, Ko G . Sonographic measurement of mesenteric fat predicts presence of fatty liver among subjects with polycystic ovary syndrome. J Clin Endocrinol Metab. 2010; 96(3):799-807. DOI: 10.1210/jc.2010-1608. View

10.

Farrell G, Wong V, Chitturi S . NAFLD in Asia--as common and important as in the West. Nat Rev Gastroenterol Hepatol. 2013; 10(5):307-18. DOI: 10.1038/nrgastro.2013.34. View

11.

Petaja E, Yki-Jarvinen H . Definitions of Normal Liver Fat and the Association of Insulin Sensitivity with Acquired and Genetic NAFLD-A Systematic Review. Int J Mol Sci. 2016; 17(5). PMC: 4881459. DOI: 10.3390/ijms17050633. View

12.

Westerbacka J, Corner A, Tiikkainen M, Tamminen M, Vehkavaara S, Hakkinen A . Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia. 2004; 47(8):1360-9. DOI: 10.1007/s00125-004-1460-1. View

13.

Croston G, Milan L, Marschke K, Reichman M, Briggs M . Androgen receptor-mediated antagonism of estrogen-dependent low density lipoprotein receptor transcription in cultured hepatocytes. Endocrinology. 1997; 138(9):3779-86. DOI: 10.1210/endo.138.9.5404. View

14.

Wang J, Xu C, Xun Y, Lu Z, Shi J, Yu C . ZJU index: a novel model for predicting nonalcoholic fatty liver disease in a Chinese population. Sci Rep. 2015; 5:16494. PMC: 4645098. DOI: 10.1038/srep16494. View

15.

Jamil A, Alalaf S, Al-Tawil N, Al-Shawaf T . A case-control observational study of insulin resistance and metabolic syndrome among the four phenotypes of polycystic ovary syndrome based on Rotterdam criteria. Reprod Health. 2015; 12:7. PMC: 4417246. DOI: 10.1186/1742-4755-12-7. View

16.

Ramezani-Binabaj M, Motalebi M, Karimi-Sari H, Rezaee-Zavareh M, Alavian S . Are women with polycystic ovarian syndrome at a high risk of non-alcoholic Fatty liver disease; a meta-analysis. Hepat Mon. 2015; 14(11):e23235. PMC: 4286712. DOI: 10.5812/hepatmon.23235. View

17.

Miyake T, Kumagi T, Hirooka M, Koizumi M, Furukawa S, Ueda T . Metabolic markers and ALT cutoff level for diagnosing nonalcoholic fatty liver disease: a community-based cross-sectional study. J Gastroenterol. 2012; 47(6):696-703. DOI: 10.1007/s00535-012-0534-y. View

18.

Kubota T . Update in polycystic ovary syndrome: new criteria of diagnosis and treatment in Japan. Reprod Med Biol. 2013; 12(3):71-77. PMC: 3695670. DOI: 10.1007/s12522-013-0145-1. View

19.

Brettenthaler N, De Geyter C, Huber P, Keller U . Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004; 89(8):3835-40. DOI: 10.1210/jc.2003-031737. View

20.

Hanson M, Gluckman P . Developmental origins of health and disease: new insights. Basic Clin Pharmacol Toxicol. 2008; 102(2):90-3. DOI: 10.1111/j.1742-7843.2007.00186.x. View